International Clinical Trial: An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients with Advanced Solid Tumor

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120399) titled 'An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients with Advanced Solid Tumor' on March 13.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Cancer Hospital of Chinese Academy of Medical Sciences

Condition: Advanced Solid Tumor

Intervention: Group 1:0.1 mg/kg T320 for injection,Q3W Group 2:0.4 mg/kg T320 for injection,Q3W Group 3:1.0 mg/kg T320 for injection,Q3W Group 4:1.5 mg/kg T320 for injection,Q3W Group 5:1.8 mg/kg T320 for...